| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/05/2013 | EP2598503A1 Cis-tetrahydrospiro(cyclohexane-1,1'-pyrido[3,4-b]indol)-4-amine derivatives |
| 06/05/2013 | EP2598502A1 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. |
| 06/05/2013 | EP2598501A1 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| 06/05/2013 | EP2598500A1 Compositions and methods for inhibition of the jak pathway |
| 06/05/2013 | EP2598499A2 Process for the preparation of imatinib mesylate |
| 06/05/2013 | EP2598498A1 Hetero-bicyclic derivatives as hcv inhibitors |
| 06/05/2013 | EP2598497A1 Cyclic amine azaheterocyclic carboxamides |
| 06/05/2013 | EP2598493A1 Matrix metalloproteinase inhibitors |
| 06/05/2013 | EP2598492A1 Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k |
| 06/05/2013 | EP2598491A1 Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| 06/05/2013 | EP2598488A1 Hydrated sodium salt form of celecoxib |
| 06/05/2013 | EP2598486A1 Bicyclic acetyl-coa carboxylase inhibitors |
| 06/05/2013 | EP2598485A2 Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same |
| 06/05/2013 | EP2598483A1 Ampk-activating heterocyclic compounds and methods for using the same |
| 06/05/2013 | EP2598482A1 Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| 06/05/2013 | EP2598480A1 Cyclopropylamine derivatives useful as lsd1 inhibitors |
| 06/05/2013 | EP2598478A2 Arylsulfonamide derivatives, compositions, and methods of use |
| 06/05/2013 | EP2598477A2 Peripherally restricted faah inhibitors |
| 06/05/2013 | EP2598206A1 A method of managing broncho-constrictive condition |
| 06/05/2013 | EP2598168A2 Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor |
| 06/05/2013 | EP2598158A1 Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex |
| 06/05/2013 | EP2598153A1 Synthetic synovial fluid compositions and methods for making the same |
| 06/05/2013 | EP2598152A1 Treatment of metabolic syndrome and insulin resistance with citrus flavanones |
| 06/05/2013 | EP2598151A1 Compositions for treating heartworm infestation |
| 06/05/2013 | EP2598150A2 Compositions for proliferation of cells and related methods |
| 06/05/2013 | EP2598149A2 Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| 06/05/2013 | EP2598148A2 Pharmaceutical compositions containing pemetrexed having extended storage stability |
| 06/05/2013 | EP2598147A1 N-methylformamide solvate of dasatinib |
| 06/05/2013 | EP2598146A1 Methods to identify targets and molecules regulating purinosomes and their uses |
| 06/05/2013 | EP2598145A1 Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| 06/05/2013 | EP2598144A1 6-(1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-ylthio)-[1,2,4] triazolo [4,3-b] pyridazine as a c-met inhibitor |
| 06/05/2013 | EP2598143A1 Pharmaceutical compositions for treatment of respiratory and inflammatory diseases |
| 06/05/2013 | EP2598142A1 Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases |
| 06/05/2013 | EP2598141A2 Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies |
| 06/05/2013 | EP2598140A2 Compounds and methods for skin repair |
| 06/05/2013 | EP2598139A2 Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments |
| 06/05/2013 | EP2598138A2 Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| 06/05/2013 | EP2598137A1 Method of treating animal drinking water with interval dosing of a biocide |
| 06/05/2013 | EP2598136A1 Dispersions of rasagiline citrate |
| 06/05/2013 | EP2598135A1 Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
| 06/05/2013 | EP2598134A1 Composition and method for photodynamic disinfection |
| 06/05/2013 | EP2598133A2 Method and therapeutic for the treatment and regulation of memory formation |
| 06/05/2013 | EP2598132A1 Composition for the treatment and prevention of herpes simplex labialis |
| 06/05/2013 | EP2598131A1 Compounds for the treatment/prevention of ocular inflammatory diseases |
| 06/05/2013 | EP2598130A1 Pharmaceutical composition for the prevention of perioperative arterial hypotension in humans |
| 06/05/2013 | EP2598129A2 Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| 06/05/2013 | EP2598128A1 Anti- viral azide-containing compounds |
| 06/05/2013 | EP2598127A1 Anti-viral azide containing compounds |
| 06/05/2013 | EP2598126A2 Methods of treating pain |
| 06/05/2013 | EP2598125A2 Novel methods for preventing or treating diabetes |
| 06/05/2013 | EP2598124A1 Three-phase controlled-release tablet comprising melatonin and process of preparation |
| 06/05/2013 | EP2598110A2 Skin care compositions comprising substituted monoamines |
| 06/05/2013 | EP2598109A1 Preservative-free composition for topical use including hyaluronic acid |
| 06/05/2013 | EP2597973A1 Nutritional compositions |
| 06/05/2013 | EP2597972A1 Use of a mixture of probiotic bacteria in a mixture with short - chain fatty acids |
| 06/05/2013 | EP2597954A1 Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| 06/05/2013 | CN202961238U Traditional Chinese medicine liquor soaked toe socks for fundamentally treating barbiers |
| 06/05/2013 | CN202960886U Temperature-displayed fever cooling patch capable of warning failure |
| 06/05/2013 | CN1946353B Naltrexone long acting formulations and methods of use |
| 06/05/2013 | CN1876641B Method for purifying salvianolic acid B |
| 06/05/2013 | CN103140588A Fermented soya based mixture comprising isoflavones- aglicones, equol and lunasil, process for the preparation and uses thereof in food, medical and cosmetic fields |
| 06/05/2013 | CN103140587A Composition containing 2-acyl-lysophosphatidylserine and method for producing same |
| 06/05/2013 | CN103140579A Use of a protein tyrosine kinase inhibitor for inducing the differentiation of mesenchymal stem cells into cardiogenic cells |
| 06/05/2013 | CN103140494A Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties |
| 06/05/2013 | CN103140490A Azaindazole compounds |
| 06/05/2013 | CN103140489A Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract |
| 06/05/2013 | CN103140488A Compounds and compositions for mitigating tissue damage and lethality |
| 06/05/2013 | CN103140486A Co-crystals and salts of ccr3-inhibitors |
| 06/05/2013 | CN103140485A Crystalline oxalate salts of a diamide compound |
| 06/05/2013 | CN103140484A Cyclic amine azaheterocyclic carboxamides |
| 06/05/2013 | CN103140481A Solid forms comprising a cyclopropyl amide derivative |
| 06/05/2013 | CN103140480A Heterocyclic compounds, their preparation and their therapeutic application |
| 06/05/2013 | CN103140476A Novel trpv3 modulators |
| 06/05/2013 | CN103140475A Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof |
| 06/05/2013 | CN103140466A Process for preparing compound by novel sandmeyer-like reaction using nitroxide radical compound as reaction catalyst |
| 06/05/2013 | CN103140228A Benzoxaborole derivatives for treating bacterial infections |
| 06/05/2013 | CN103140227A Processes for preparing tubulysins |
| 06/05/2013 | CN103140226A Preparation for treatment of spinal cord injury |
| 06/05/2013 | CN103140225A Methods of treatment of pancreatic cancer |
| 06/05/2013 | CN103140224A An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| 06/05/2013 | CN103140223A Use of jasmonates for treating heart failure and related cardiac disorders |
| 06/05/2013 | CN103140222A Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin |
| 06/05/2013 | CN103140221A Novel heterocyclic derivatives and pharmaceutical composition containing same |
| 06/05/2013 | CN103140217A Combination of compounds for treating or preventing skin diseases |
| 06/05/2013 | CN103140211A Skin care compositions comprising substituted monoamines |
| 06/05/2013 | CN103140134A Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| 06/05/2013 | CN103131736A Preparation and application of high-purity lysophosphatidylcholine |
| 06/05/2013 | CN103130865A Sophocarpidine, oxymatrine glycyrrhetinic acid double salt, and preparation method and use thereof |
| 06/05/2013 | CN103130860A Diflucortolone valerate novel crystal form and topical external preparation prepared by same |
| 06/05/2013 | CN103130859A Difluprednate crystal form I and preparation method thereof |
| 06/05/2013 | CN103130857A Difluprednate II crystal form and preparation method thereof |
| 06/05/2013 | CN103130854A Vitamin E succinic acid esterification gemcitabine prodrug and application |
| 06/05/2013 | CN103130853A Roxithromycin (ROX) crystal C type matter, preparation method thereof, medicine composition thereof and uses thereof |
| 06/05/2013 | CN103130852A Erythrocin A derivative, preparation method thereof, intermediate and application |
| 06/05/2013 | CN103130848A Macrolide antibacterial compounds, and preparation method and application thereof |
| 06/05/2013 | CN103130836A Platinum (II) complexes having antitumor activities, and preparation methods thereof |
| 06/05/2013 | CN103130828A Methocarbamol diammonium phosphate, and polymorphism and preparation method thereof |
| 06/05/2013 | CN103130821A Cefuroxime lysine and preparation thereof |
| 06/05/2013 | CN103130819A Thiophene [3, 2-d] combined pyrimidine-4-ketone compound and preparation method thereof and medicine combination and application |
| 06/05/2013 | CN103130815A Isosorbide mononitrate derivative and preparation method and application thereof |